Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 30, Issue 16, 2012, Pages 2019-2020

  Edelman, Martin J ^a   Hodgson, Lydia ^b   Wang, Xiaofei ^b   Kratzke, Robert A ^c   Vokes, Everett E ^d  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRICOXIB; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2; DOCETAXEL; ERLOTINIB; GEMCITABINE; PROSTAGLANDIN E2; TAXANE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ENZYME INHIBITION; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863937925     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.41.4581     Document Type: Letter

References (9)

1. Groen HJ, Sietsma H, Vincent A, et al: Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: The NVALT-4 study. J Clin Oncol 29:4320-4326, 2011
2. Edelman MJ, Watson D, Wang X, et al: Eicosanoid modulation in advanced lung cancer: Cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy - Cancer and Leukemia Group B Trial 30203. J Clin Oncol 26:848-855, 2008 (Pubitemid 351398075)
3. Subbaramaiah K, Hart JC, Norton L, et al: Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2: Evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem 275:14838-14845, 2000 (Pubitemid 30337196)
4. Altorki NK, Port JL, Zhang F, et al: Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 11:4191-4197, 2005 (Pubitemid 40791585)
5. Fidler MJ, Argiris A, Patel JD, et al: The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with and erlotinib and celecoxib. Clin Cancer Res 14:2088-2094, 2008 (Pubitemid 351551120)
6. Rini BI, Weinberg V, Dunlap S, et al: Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106:566-575, 2006 (Pubitemid 43157619)
7. Fabi A, Metro G, Papaldo P, et al: Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: Results of a phase II study with biomarker evaluation. Cancer Chemother Pharmacol 62:717-725, 2008
8. Gitlitz BJ, Bernstein ED, Keogh GP, et al: Apricot-l: Results of a biomarker-based phase II randomized placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer (NSCLC) patients. J Clin Oncol 29:482s, 2011 (suppl 15; abstr 7528)
9. Reckamp KL, Krysan K, Morrow JD, et al: A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12:3381-3388, 2006